225 related articles for article (PubMed ID: 35121901)
1. The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.
Adam S; Rossi SE; Moatti N; De Marco Zompit M; Xue Y; Ng TF; Álvarez-Quilón A; Desjardins J; Bhaskaran V; Martino G; Setiaputra D; Noordermeer SM; Ohsumi TK; Hustedt N; Szilard RK; Chaudhary N; Munro M; Veloso A; Melo H; Yin SY; Papp R; Young JTF; Zinda M; Stucki M; Durocher D
Nat Cancer; 2021 Dec; 2(12):1357-1371. PubMed ID: 35121901
[TBL] [Abstract][Full Text] [Related]
2. The CIP2A-TOPBP1 complex safeguards chromosomal stability during mitosis.
De Marco Zompit M; Esteban MT; Mooser C; Adam S; Rossi SE; Jeanrenaud A; Leimbacher PA; Fink D; Shorrocks AK; Blackford AN; Durocher D; Stucki M
Nat Commun; 2022 Jul; 13(1):4143. PubMed ID: 35842428
[TBL] [Abstract][Full Text] [Related]
3. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.
Laine A; Nagelli SG; Farrington C; Butt U; Cvrljevic AN; Vainonen JP; Feringa FM; Grönroos TJ; Gautam P; Khan S; Sihto H; Qiao X; Pavic K; Connolly DC; Kronqvist P; Elo LL; Maurer J; Wennerberg K; Medema RH; Joensuu H; Peuhu E; de Visser K; Narla G; Westermarck J
Cancer Res; 2021 Aug; 81(16):4319-4331. PubMed ID: 34145035
[TBL] [Abstract][Full Text] [Related]
4. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of the CIP2A-TopBP1 complex in genome integrity.
Ummethum H; Li J; Lisby M; Oestergaard VH
NAR Cancer; 2023 Dec; 5(4):zcad052. PubMed ID: 37829116
[TBL] [Abstract][Full Text] [Related]
6. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
[TBL] [Abstract][Full Text] [Related]
7. Oocytes can repair DNA damage during meiosis via a microtubule-dependent recruitment of CIP2A-MDC1-TOPBP1 complex from spindle pole to chromosomes.
Leem J; Kim JS; Oh JS
Nucleic Acids Res; 2023 Jun; 51(10):4899-4913. PubMed ID: 36999590
[TBL] [Abstract][Full Text] [Related]
8. MDC1 Interacts with TOPBP1 to Maintain Chromosomal Stability during Mitosis.
Leimbacher PA; Jones SE; Shorrocks AK; de Marco Zompit M; Day M; Blaauwendraad J; Bundschuh D; Bonham S; Fischer R; Fink D; Kessler BM; Oliver AW; Pearl LH; Blackford AN; Stucki M
Mol Cell; 2019 May; 74(3):571-583.e8. PubMed ID: 30898438
[TBL] [Abstract][Full Text] [Related]
9. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
10. CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response.
Nagelli S; Westermarck J
Trends Cancer; 2024 Jan; 10(1):52-64. PubMed ID: 37793965
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
12. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
13. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
14. MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.
Srinivasan G; Williamson EA; Kong K; Jaiswal AS; Huang G; Kim HS; Schärer O; Zhao W; Burma S; Sung P; Hromas R
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17438-17443. PubMed ID: 31395736
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Predisposition Genes and Synthetic Lethality.
Neiger HE; Siegler EL; Shi Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070674
[No Abstract] [Full Text] [Related]
16. CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress.
Przetocka S; Porro A; Bolck HA; Walker C; Lezaja A; Trenner A; von Aesch C; Himmels SF; D'Andrea AD; Ceccaldi R; Altmeyer M; Sartori AA
Mol Cell; 2018 Nov; 72(3):568-582.e6. PubMed ID: 30344097
[TBL] [Abstract][Full Text] [Related]
17. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
[TBL] [Abstract][Full Text] [Related]
18. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
19. Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Carbajosa S; Pansa MF; Paviolo NS; Castellaro AM; Andino DL; Nigra AD; García IA; Racca AC; Rodriguez-Berdini L; Angiolini V; Guantay L; Villafañez F; Federico MB; Rodríguez-Baili MC; Caputto BL; Drewes G; Madauss KP; Gloger I; Fernandez E; Gil GA; Bocco JL; Gottifredi V; Soria G
Clin Cancer Res; 2019 Jul; 25(13):4049-4062. PubMed ID: 30890549
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
